Lv61
3125 积分 2022-01-12 加入
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
4天前
已完结
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
16天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
16天前
已完结
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
17天前
已完结
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
17天前
已关闭
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
18天前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
18天前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
19天前
已完结
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review
1个月前
已完结
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
1个月前
已完结
皖公网安备34019202002308
